Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
NEW YORK, April 15, 2024--Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
(Bloomberg) -- Hand sanitizers were tainted by benzene. Sunscreens and dry shampoos too. Now acne treatments are joining the list of widely used consumer products found to contain high levels of the chemical linked to cancer.Most Read from BloombergChemical Linked to Cancer Found in Acne Creams Including Proactiv, ClearasilHow Trump’s Ex-Treasury Chief Landed 2024's Highest-Profile US Bank DealNikki Haley Ends 2024 Bid, Setting Up Trump-Biden RematchNew York to Deploy National Guard to NYC Subwa
Krensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Ltd.'s bid for Taro Pharmaceutical Industries Ltd.
HAWTHORNE, N.Y., January 25, 2024--TARO PROVIDES RESULTS FOR DECEMBER 31, 2023
The Indian drugmaker, which currently owns about 78.5% stake in Taro, had offered to buy its remaining stake for $38 per share in May. Upon completion of the merger, which is expected to close in the first half of the year, Taro would become a privately held company and will be delisted from the New York Stock Exchange, the companies said. The U.S. government had in November dismissed charges against a former Taro executive who was accused of conspiring to fix generic drug prices between 2013 ...
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that they have entered into a definitive merger agreement in which Sun Pharma, Taro's controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Ph
Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.
Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.
The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.
Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.